Oncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm?

Bibliography

• Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009;373(9669):1119-32
   PubMed Web of Science ®Google Scholar
• Oosterwijk E, Rathmell WK, Junker K, Basic research in kidney cancer. Eur Urol 2011;60(4):622-33
   PubMed Web of Science ®Google Scholar
• Kovacs G, Akhtar M, Beckwith BJ, The Heidelberg classification of renal cell tumours. J Pathol 1997;183(2):131-3
   PubMed Web of Science ®Google Scholar
• Jeldres C, Baillargeon-Gagne S, Liberman D, A population-based analysis of the rate of cytoreductive nephrectomy for metastatic renal cell carcinoma in the United States. Urology 2009;74(4):837-41
   PubMed Web of Science ®Google Scholar
• Permpongkosol S, Bagga HS, Romero FR, Laparoscopic versus open partial nephrectomy for the treatment of pathological T1N0M0 renal cell carcinoma: a 5-year survival rate. J Urol 2006;176(5):1984-8
   PubMed Web of Science ®Google Scholar
• Lane BR, Gill IS. 7-year oncological outcomes after laparoscopic and open partial nephrectomy. J Urol 2010;183(2):473-9
   PubMed Web of Science ®Google Scholar
• Sun M, Lughezzani G, Perrotte P, Treatment of metastatic renal cell carcinoma. Nat Rev Urol 2010;7(6):327-38
   PubMed Web of Science ®Google Scholar
• Zini L, Capitanio U, Perrotte P, Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology 2009;73(2):342-6
   PubMed Web of Science ®Google Scholar
• Alvarez M, Paull K, Monks A, Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Invest 1995;95(5):2205-14
   PubMed Web of Science ®Google Scholar
• Lusini L, Tripodi SA, Rossi R, Altered glutathione anti-oxidant metabolism during tumor progression in human renal-cell carcinoma. Int J Cancer 2001;91(1):55-9
   PubMed Web of Science ®Google Scholar
• McDermott DF. Immunotherapy of metastatic renal cell carcinoma. Cancer 2009;115(10 Suppl):2298-305
   PubMed Web of Science ®Google Scholar
• Negrier S, Escudier B, Lasset C, Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma: Groupe Francais d’Immunotherapie. N Engl J Med 1998;338(18):1272-8
   PubMed Web of Science ®Google Scholar
• Stewart GD, O'Mahony FC, Powles T, What can molecular pathology contribute to the management of renal cell carcinoma? Nat Rev Urol 2011;8(5):255-65
   PubMed Web of Science ®Google Scholar
• Thirukkumaran C, Morris DG. Oncolytic viral therapy using reovirus. Methods Mol Biol 2009;542:607-34
   PubMedGoogle Scholar
• Stanford MM, Breitbach CJ, Bell JC, Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes? Curr Opin Mol Ther 2008;10(1):32-7
   PubMed Web of Science ®Google Scholar
• Prestwich RJ, Harrington KJ, Pandha HS, Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther 2008;8(10):1581-8
   PubMed Web of Science ®Google Scholar
• Latif F, Tory K, Gnarra J, Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260(5112):1317-20
   PubMed Web of Science ®Google Scholar
• Foster K, Prowse A, van den Berg A, Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 1994;3(12):2169-73
   PubMed Web of Science ®Google Scholar
• Gnarra JR, Tory K, Weng Y, Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7(1):85-90
   PubMed Web of Science ®Google Scholar
• Banumathy G, Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biol Ther 2010;10(7):658-64
   PubMed Web of Science ®Google Scholar
• Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002;2(9):673-82
   PubMed Web of Science ®Google Scholar
• Ohh M, Park CW, Ivan M, Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000;2(7):423-7
   PubMed Web of Science ®Google Scholar
• Baldewijns MM, van Vlodrop IJ, Vermeulen PB. VHL and HIF signalling in renal cell carcinogenesis. J Pathol 2010;221(2):125-38
   PubMed Web of Science ®Google Scholar
• Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010;29(5):625-34
   PubMed Web of Science ®Google Scholar
• Gollob JA, Wilhelm S, Carter C, Role of raf kinase in cancer: therapeutic potential of targeting the RAF/MEK/ERK signal transduction pathway. Semin Oncol 2006;33(4):392-406
   PubMed Web of Science ®Google Scholar
• Elfiky AA, Aziz SA, Conrad PJ, Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. J Transl Med 2011;9:133-3
   PubMedGoogle Scholar
• Coffey MC, Strong JE, Forsyth PA, Reovirus therapy of tumors with activated Ras pathway. Science 1998;282(5392):1332-4
   PubMed Web of Science ®Google Scholar
• Parato KA, Breitbach CJ, Le Boeuf F, The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther 2012;20(4):749-58
   PubMed Web of Science ®Google Scholar
• Farassati F, Yang AD, Lee PW. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 2001;3(8):745-50
   PubMed Web of Science ®Google Scholar
• Shinohara N, Ogiso Y, Tanaka M, The significance of Ras guanine nucleotide exchange factor, son of sevenless protein, in renal cell carcinoma cell lines. J Urol 1997;158(3 Pt 1):908-11
   PubMed Web of Science ®Google Scholar
• Werden SJ, McFadden G. Pharmacological manipulation of the akt signaling pathway regulates myxoma virus replication and tropism in human cancer cells. J Virol 2010;84(7):3287-302
   PubMed Web of Science ®Google Scholar
• Sourbier C, Lindner V, Lang H, The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer Res 2006;66(10):5130-42
   PubMed Web of Science ®Google Scholar
• Roos FC, Roberts AM, Hwang II, Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus. EMBO Mol Med 2010;2(7):275-88
   PubMed Web of Science ®Google Scholar
• Kuroda T, Rabkin SD, Martuza RL, Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. Cancer Res 2006;66(20):10127-35
   PubMed Web of Science ®Google Scholar
• Junker H, Venz S, Zimmerman U, Stage-related alterations in renal cell carcinoma – comprehensive quantitative analysis by the 2D-DIGE and protein network analysis. Plos one 2011;6(7):e21867-7
   PubMedGoogle Scholar
• Dalgliesh GL, Furge K, Greenman C, Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010;463(7279):360-3
   PubMed Web of Science ®Google Scholar
• Varela I, Tarpey P, Raine K, Exome sequencing identifies frequent mutation of the SWI/SNF Complex gene PBRM1 in renal carcinoma. Nature 2011(7331):539-42
   PubMed Web of Science ®Google Scholar
• Chang AE, Li Q, Jiang G, Phase II trial of autologous tumour vaccination, anti-cd3-activated vaccine primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol 2003;21(5):884-90
   PubMed Web of Science ®Google Scholar
• Kujawski M, Zhang C, Herrmann A, Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer res 2010;70(23):9599-610
   PubMed Web of Science ®Google Scholar
• Childs R, Chernoff A, Contentin N, Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343(11):750-8
   PubMed Web of Science ®Google Scholar
• Lesimple T, Moisan A, Guille F, Treatment of metastatic renal cell carcinoma with activated autologous macrophages and granulocyte-macrophage colony-stimulating factor. J Immunother 2000;23(6):675-9
   PubMed Web of Science ®Google Scholar
• Golumbek PT, Lazenby AJ, Levitsky HI, Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254(5032):713-16
   PubMed Web of Science ®Google Scholar
• Draube A, Klein-Gonzalez N, Mattheus S, Dendritic cell based tumor vaccination in prostate and RCC: a systematic review and meta-analysis. Plos one 2011;6(4):e18801-1
   PubMed Web of Science ®Google Scholar
• Steele L, Errington F, Prestwich R, Proinflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-kappabeta mediated and supports innate and adaptive anti-tumour immune priming. Mol cancer 2011;10:20-0
   PubMed Web of Science ®Google Scholar
• Pesonen S, Kangasniemi L, Hemminki A. Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm 2011;8(1):12-28
   PubMedGoogle Scholar
• Cuevas Y, Hernandez-Alcoceba R, Aragones J, Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas. Cancer Res 2003;63(20):6877-84
   PubMed Web of Science ®Google Scholar
• Guse K, Diaconu I, Rajecki M, Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment. Gene Ther 2009;16(8):1009-20
   PubMed Web of Science ®Google Scholar
• Huang P, Kaku H, Chen J, Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and IL-2 in a mouse model of renal cell carcinoma. Cancer Gene Ther 2010;17(7):484-91
   PubMed Web of Science ®Google Scholar
• Zhang ZL, Zou WG, Luo CX, An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res 2003;13:481-9
   PubMed Web of Science ®Google Scholar
• Zheng JN, Pei DS, Sun FH, Potent antitumor efficacy of interleukin-18 delivered by conditionally replicative adenovirus vector in renal cell carcinoma-bearing nude mice via inhibition of angiogenesis. Cancer Biol Ther 2009;8(7):599-606
   PubMed Web of Science ®Google Scholar
• Zheng JN, Pei DS, Mao LJ, Inhibition of renal cancer cell growth in vitro and in vivo with oncolytic adenovirus armed short hairpin RNA targeting Ki-67 encoding mRNA. Cancer Gene Ther 2009;16(1):20-32
   PubMed Web of Science ®Google Scholar
• Zheng JN, Pei DS, Sun FH, Inhibition of renal cancer cell growth by oncolytic adenovirus armed short hairpin RNA targeting hTERT gene. Cancer Biol Ther 2009;8(1):84-91
   PubMed Web of Science ®Google Scholar
• Guse K, Ranki T, Ala-Opas M, Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses. Mol Cancer Ther 2007;6(10):2728-36
   PubMed Web of Science ®Google Scholar
• Hwang KS, Cho WK, Yoo J, Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity. Cancer Gene Ther 2004;11(6):397-407
   PubMed Web of Science ®Google Scholar
• Wang L, Qi X, Sun Y, Adenovirus-mediated combined P16 gene and GM-CSF gene therapy for the treatment of established tumor and induction of antitumor immunity. Cancer Gene Ther 2002;9(10):819-24
   PubMed Web of Science ®Google Scholar
• Tosch C, Geist M, Ledoux C, Adenovirus-mediated gene transfer of pathogen-associated molecular patterns for cancer immunotherapy. Cancer Gene Ther 2009;16(4):310-19
   PubMed Web of Science ®Google Scholar
• Zhang M, Berndt BE, Chen JJ, Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy. J Immunol 2008;181(5):3690-7
   PubMed Web of Science ®Google Scholar
• Guse K, Cerullo V, Hemminki A. Oncolytic vaccinia virus for the treatment of cancer. Expert Opin Biol Ther 2011;11(5):595-608
   PubMed Web of Science ®Google Scholar
• Thorne SH. Immunotherapeutic potential of oncolytic vaccinia virus. Immunol Res 2011;50(2-3):286-93
   PubMed Web of Science ®Google Scholar
• Breitbach CJ, Burke J, Jonker D, Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011;477(7362):99-102
   PubMed Web of Science ®Google Scholar
• Guse K, Sloniecka M, Diaconu I, Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. J Virol 2010;84(2):856-66
   PubMed Web of Science ®Google Scholar
• Arakawa S Jr, Hamami G, Umezu K, Clinical trial of attenuated vaccinia virus AS strain in the treatment of advanced adenocarcinoma. Report on two cases. J Cancer Res Clin Oncol 1987;113(1):95-8
   PubMed Web of Science ®Google Scholar
• Campadelli-Fiume G, De Giovanni C, Gatta V, Rethinking herpes simplex virus: the way to oncolytic agents. Rev Med Virol 2011;21(4):213-26
   PubMed Web of Science ®Google Scholar
• Oyama M, Ohigashi T, Hoshi M, Treatment of human renal cell carcinoma by a conditionally replicating herpes vector G207. J Urol 2001;165(4):1274-8
   PubMed Web of Science ®Google Scholar
• Fu X, Nakamori M, Tao L, Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma. Int J Oncol 2007;30(6):1561-7
   PubMed Web of Science ®Google Scholar
• Inoue M, Tokusumi Y, Ban H, A new Sendai virus vector deficient in the matrix gene does not form virus particles and shows extensive cell-to-cell spreading. J Virol 2003;77(11):6419-29
   PubMed Web of Science ®Google Scholar
• Kinoh H, Inoue M, Washizawa K, Generation of a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases. Gene Ther 2004;11(14):1137-45
   PubMed Web of Science ®Google Scholar
• Kinoh H, Inoue M, Komaru A, Generation of optimized and urokinase-targeted oncolytic Sendai virus vectors applicable for various human malignancies. Gene Ther 2009;16(3):392-403
   PubMed Web of Science ®Google Scholar
• Fujihara A, Kurooka M, Miki T, Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. Cancer Immunol Immunother 2008;57(1):73-84
   PubMed Web of Science ®Google Scholar
• Galanis E. Therapeutic potential of oncolytic measles virus: promises and challenges. Clin Pharmacol Ther 2010;88(5):620-5
   PubMed Web of Science ®Google Scholar
• Meng X, Nakamura T, Okazaki T, Enhanced antitumor effects of an engineered measles virus edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma. Mol Ther 2010;18(3):544-51
   PubMed Web of Science ®Google Scholar
• Lichty BD, Power AT, Stojdl DF, Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med 2004;10(5):210-16
   PubMed Web of Science ®Google Scholar
• Kottke T, Errington F, Pulido J, Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat Med 2011;17(7):854-9
   PubMed Web of Science ®Google Scholar
• Hwang II, Watson IR, Der SD, Loss of VHL confers hypoxia-inducible factor (HIF)-dependent resistance to vesicular stomatitis virus: role of HIF in antiviral response. J Virol 2006;80(21):10712-23
   PubMed Web of Science ®Google Scholar
• Cho IR, Koh SS, Min HJ, Down-regulation of HIF-1alpha by oncolytic reovirus infection independently of VHL and p53. Cancer Gene Ther 2010;17(5):365-72
   PubMed Web of Science ®Google Scholar
• Craighead JE, McLane MF. Diabetes mellitus: induction in mice by encephalomyocarditis virus. Science 1968;162(3856):913-14
   PubMed Web of Science ®Google Scholar
• Schwarz EM, Badorff C, Hiura TS, NF-kappaB-mediated inhibition of apoptosis is required for encephalomyocarditis virus virulence: a mechanism of resistance in p50 knockout mice. J Virol 1998;72(7):5654-60
   PubMed Web of Science ®Google Scholar
• Wojton J, Kaur B. Impact of tumor microenvironment on oncolytic viral therapy. Cytokine Growth Factor Rev 2010;21(2-3):127-34
   PubMed Web of Science ®Google Scholar
• Tatsumi T, Herrem CJ, Olson WC, Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 2003;63(15):4481-9
   PubMed Web of Science ®Google Scholar
• Fulci G, Breymann L, Gianni D, Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 2006;103(34):12873-8
   PubMed Web of Science ®Google Scholar
• Ikeda K, Wakimoto H, Ichikawa T, Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol 2000;74(10):4765-75
   PubMed Web of Science ®Google Scholar
• K, IkedaIchikawa T, Wakimoto H, Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999;5(8):881-7
   PubMed Web of Science ®Google Scholar
• White CL, Twigger KR, Vidal L, Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther 2008;15(12):911-20
   PubMed Web of Science ®Google Scholar
• Willmon C, Diaz RM, Wongthida P, Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide. Mol Ther 2011;19(1):140-9
   PubMed Web of Science ®Google Scholar
• Woller N, Knocke S, Mundt B, Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice. J Clin Invest 2011;121(7):2570-82
   PubMed Web of Science ®Google Scholar
• Kottke T, Galivo F, Wongthida P, Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol Ther 2008;16(7):1217-26
   PubMed Web of Science ®Google Scholar
• Kottke T, Thompson J, Diaz RM, Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated treg modulation and interleukin-2. Clin Cancer Res 2009;15(2):561-9
   PubMed Web of Science ®Google Scholar
• Ochoa AC, Zea AH, Hernandez C, Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007;13(2 Pt 2):721s-726s
   PubMed Web of Science ®Google Scholar
• Cesana GC, DeRaffele G, Cohen S, Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006;24(7):1169-77
   PubMed Web of Science ®Google Scholar
• Hegele A, Varga Z, von Knobloch R, TGF-beta1 in patients with renal cell carcinoma. Urol Res 2002;30(2):126-9
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62
   PubMed Web of Science ®Google Scholar
• Anderson H, Yap JT, Wells P, Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. Br J Cancer 2003;89(2):262-7
   PubMed Web of Science ®Google Scholar
• Dickson PV, Hamner JB, Streck CJ, Continuous delivery of IFN-B promotes sustained maturation of intratumoral vasculature. Mol Cancer Res 2007;5(6):531-42
   PubMed Web of Science ®Google Scholar
• Yazawa H, Murakami T, Li HM, Hydrodynamics-based gene delivery of naked DNA encoding fetal liver kinase-1 gene effectively suppresses the growth of pre-existing tumors. Cancer Gene Ther 2006;13(11):993-1001
   PubMed Web of Science ®Google Scholar
• Ko JS, Zea AH, Rini BI, Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15(6):2148-57
   PubMed Web of Science ®Google Scholar
• Finke JH, Rini B, Ireland J, Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14(20):6674-82
   PubMed Web of Science ®Google Scholar
• Bose A, Taylor JL, Alber S, Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer 2011;129:2158-70
   PubMed Web of Science ®Google Scholar
• Farsaci B, Higgins JP, Hodge JW. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer 2012;130(8):1948-59
   PubMed Web of Science ®Google Scholar
• Kusmartsev S, Eruslanov E, Kubler H, Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol 2008;181(1):346-53
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9(3):162-74
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Ernstoff MS, Hernandez C, Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009;69(4):1553-60
   PubMed Web of Science ®Google Scholar
• Zhou Q, Gallo JM. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. Neuro Oncol 2009;11(3):301-10
   PubMed Web of Science ®Google Scholar
• Dickson PV, Hamner JB, Sims TL, Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007;13(13):3942-50
   PubMed Web of Science ®Google Scholar
• Hillman GG, Singh-Gupta V, Al-Bashir AK, Dynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors. Transl Oncol 2010;3(5):293-306
   PubMed Web of Science ®Google Scholar
• Li Q, Rao RR, Araki K, A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. Immunity 2011;34(4):541-53
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang X-Y, Subjeck JR, Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. Br J Cancer 2011;104:643-52
   PubMed Web of Science ®Google Scholar
• Bassett JD, Swift SL, VanSeggelen H, Combined mTOR inhibition and OX40 agonism enhances CD8+ T cell memory and protective immunity produced by recombinant adenovirus vaccines. Mol Ther 2012;20(4):860-9
   PubMed Web of Science ®Google Scholar